
KZR Stock Forecast & Price Target
KZR Analyst Ratings
Bulls say
Kezar Life Sciences has recently made notable progress in its clinical development pipeline, particularly with the lifting of the partial clinical hold for KZR-616, which bodes well for its risk–benefit profile in autoimmune hepatitis (AIH). The potential full removal of the clinical hold in lupus nephritis (LN) represents a significant opportunity for the company, as it may lead to resumed development and subsequent pursuit of regulatory approval in this disease setting. Overall, these developments are viewed positively, as they enhance investor confidence and could expand the commercial outlook for Kezar's key assets.
Bears say
Kezar Life Sciences Inc has reported a substantial increase in operating expenses, which may strain financial resources and hinder future growth potential. Furthermore, the company's reliance on advancing its clinical pipeline, particularly its lead candidates Zetomipzomib and KZR-261, poses significant risks given the inherent uncertainties in clinical trial outcomes and regulatory approvals. Lastly, the lack of revenue generation at this stage amplifies concerns about long-term sustainability and the ability to fund ongoing development initiatives.
This aggregate rating is based on analysts' research of Kezar Life Sciences Inc and is not a guaranteed prediction by Public.com or investment advice.
KZR Analyst Forecast & Price Prediction
Start investing in KZR
Order type
Buy in
Order amount
Est. shares
0 shares